Marwah Medicine

Medical, Medicine, Medicine classes

A PCSK9 Inhibitor in a Tablet? Meet Enlicitide, the New Oral Cholesterol Drug

For years, there was an easy examination question: “What is the major disadvantage of PCSK9 inhibitors?” One obvious answer was: they are injectable. Not anymore. On July 17, 2026, the US FDA approved enlicitide, marketed as Lipfendra, making it the first FDA-approved oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). In the pivotal clinical program, oral enlicitide produced roughly 56–59% placebo-adjusted reductions in LDL cholesterol at 24 weeks. For a once-daily tablet, that number deserves attention. HIGH-YIELD ONE-LINER: Enlicitide = first oral PCSK9 inhibitor that lowers LDL-C by 65%. WOW!   First, revise PCSK9 in 30 seconds The liver removes circulating LDL cholesterol using LDL receptors. After an LDL particle binds its receptor, the complex is internalized into the hepatocyte. Normally, the LDL receptor can be recycled back to the hepatocyte surface and used again. PCSK9 binds LDL receptors and promotes their degradation. ↑ PCSK9 → ↓ LDL receptors → ↑ circulating LDL-C Block PCSK9 → ↑ recycled LDL receptors → ↑ LDL clearance → ↓ LDL-C That is why PCSK9 became such an attractive therapeutic target. But didn’t we already have PCSK9 drugs? Yes. Alirocumab and evolocumab are monoclonal antibodies targeting PCSK9 and are administered subcutaneously. Inclisiran approaches the pathway differently: it uses small-interfering RNA to reduce hepatic PCSK9 synthesis and is also injectable. The conceptual change with enlicitide is simple: PCSK9 lowering has entered the tablet era. How effective is enlicitide? The FDA approval was supported by randomized, double-blind, placebo-controlled studies in adults with hypercholesterolemia receiving background lipid-lowering therapy. The primary efficacy measure was percentage change in LDL-C at week 24. Population Approx. baseline LDL-C Placebo-adjusted LDL-C reduction at week 24 ASCVD/high cardiovascular risk 96 mg/dL ~56% Heterozygous familial hypercholesterolemia 119 mg/dL ~59% These are substantial LDL reductions and explain why an oral PCSK9 inhibitor has generated considerable clinical interest. The CORALreef story In the Phase 3 CORALreef Lipids study, nearly all participants were receiving statins. At week 24, LDL-C fell markedly with enlicitide while remaining essentially unchanged in the placebo group. Enlicitide also reduced non-HDL cholesterol, apolipoprotein B and lipoprotein(a). The key teaching point is that enlicitide was not developed simply as a replacement for statins in untreated patients. It is a potent additional LDL-lowering option for patients who remain above their recommended LDL level despite background therapy. How does it compare with other oral non-statin drugs? The CORALreef AddOn study provided a useful short-term comparison in statin-treated patients whose LDL remained above target. At day 56, the reported mean LDL-C reductions were approximately: Treatment Approx. LDL-C reduction Enlicitide 65% Ezetimibe 28% Bempedoic acid 6% Bempedoic acid + ezetimibe 37% These are lipid-efficacy comparisons over a relatively short period, not comparisons of cardiovascular outcomes. They nevertheless illustrate the potency of oral PCSK9 inhibition. Does enlicitide replace statins? No. Statins remain foundational therapy for LDL lowering and cardiovascular risk reduction in appropriate patients. The more useful clinical question is what to add when statin therapy does not lower LDL sufficiently, or when treatment needs to be individualized because of tolerance, risk, access or other clinical considerations. Depending on the patient, non-statin options may include ezetimibe, bempedoic acid and PCSK9-directed therapies. Why 2026 is a big year for LDL management The 2026 ACC/AHA dyslipidemia guideline also updated the way clinicians think about lipid management, including explicit LDL-C goals and use of PREVENT-ASCVD equations for primary-prevention risk assessment. Borderline/intermediate-risk primary prevention: LDL-C <100 mg/dL High-risk primary prevention: LDL-C <70 mg/dL Very-high-risk ASCVD: LDL-C <55 mg/dL Very-high-risk ASCVD → think LDL-C <55 mg/dL. The guideline also emphasizes measuring lipoprotein(a), or Lp(a), at least once in adulthood. Together, the new guideline and the arrival of an oral PCSK9 inhibitor make lipid management one of the most important cardiovascular update areas of 2026. Is enlicitide safe? Across the major studies, overall adverse-event rates were broadly comparable between enlicitide and placebo. Reported adverse reactions included symptoms such as diarrhea and dizziness in relevant study populations. As with any newly introduced therapy, prescribing should follow the approved product information and the patient’s individual clinical context. A new drug should not be prescribed merely because an LDL value is elevated. Absolute cardiovascular risk, LDL level, prior therapy, tolerability, comorbidities and current guideline recommendations remain central. The limitation every doctor should understand Enlicitide has demonstrated powerful LDL lowering. But lowering LDL in a lipid-efficacy trial and directly demonstrating fewer myocardial infarctions, strokes or cardiovascular deaths are not identical endpoints. The pivotal studies established strong lipid effects. Long-term cardiovascular outcome evidence will be important in defining the drug’s ultimate place in preventive cardiology. The scientifically correct message today is: enlicitide markedly lowers LDL; the magnitude of its eventual cardiovascular-outcome benefit should be judged from dedicated outcome evidence. NEET-PG / INI-CET / FMGE Exam Box A patient with hypercholesterolemia is prescribed the first FDA-approved oral inhibitor of PCSK9. Which drug has been prescribed? Inclisiran Evolocumab Enlicitide Alirocumab Answer: C. Enlicitide Make these associations automatic: Enlicitide → oral PCSK9 inhibitor Evolocumab / Alirocumab → monoclonal antibodies against PCSK9 Inclisiran → siRNA → decreases hepatic PCSK9 synthesis The bigger story This is not simply another cholesterol tablet. For years, PCSK9-directed treatment meant an injection. Enlicitide changes that practical assumption. Whether oral administration substantially expands PCSK9 use will depend on cardiovascular outcome evidence, long-term safety, cost, availability and real-world adherence. But one fact has already changed: PCSK9 inhibition is no longer an injection-only strategy. And that is precisely the kind of update that separates current clinical medicine from an outdated textbook. Keep Hammering. Frequently Asked Questions What is the first oral PCSK9 inhibitor? Enlicitide (Lipfendra) is the first FDA-approved oral PCSK9 inhibitor. It was approved in July 2026 for adults with hypercholesterolemia, including HeFH. How much does enlicitide lower LDL cholesterol? Pivotal studies reported placebo-adjusted LDL-C reductions of roughly 56% at week 24 in an ASCVD/high-risk population and roughly 59% in patients with HeFH. Is enlicitide an injection? No. Enlicitide is an oral once-daily therapy, distinguishing it from previously approved injectable PCSK9-directed treatments. […]

INICET, Medical, Medicine, Medicine classes, NExT, NExT Exam

FDA Approves First Oral Drug for Dermatomyositis

Brepocitinib (Lisraya) Explained: Mechanism, VALOR Trial, Dose, Safety & Exam Pearls By Dr Deepak Marwah  |  Marwah Medicine A major change has arrived in dermatomyositis treatment. On August 27, 2026, the US FDA approved brepocitinib (Lisraya) tablets for adults with dermatomyositis, making it the first FDA-approved oral treatment specifically indicated for adult dermatomyositis. HIGH-YIELD ONE-LINER Brepocitinib = oral selective TYK2-JAK1 inhibitor → adult dermatomyositis. For medical students, that one line may be enough to answer a future NEET-PG, INI-CET or FMGE update question. For clinicians, however, the story is more interesting: the Phase 3 VALOR trial showed meaningful improvement in overall dermatomyositis activity, skin disease, physical function and glucocorticoid tapering with the 30-mg dose. Why this approval matters Dermatomyositis is a systemic autoimmune inflammatory myopathy. The classic teaching focuses on proximal muscle weakness, heliotrope rash and Gottron papules, but clinically the disease may involve skin, muscle, joints, lungs and other organs. Treatment has traditionally relied heavily on glucocorticoids and other immunomodulatory therapies, many used off-label. A specifically approved oral targeted therapy therefore represents an important change in the treatment landscape. What exactly is brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1. These kinases participate in intracellular cytokine signaling pathways involved in immune activation and inflammation. Think of the pathway as: Cytokine signal → JAK/TYK signaling → inflammatory gene signaling → immune-mediated tissue injury. By inhibiting TYK2 and JAK1, brepocitinib modifies several inflammatory signaling pathways implicated in dermatomyositis. The study behind the approval: VALOR The pivotal evidence came from the Phase 3 VALOR trial, a double-blind randomized placebo-controlled study involving 241 adults with dermatomyositis. Participants received brepocitinib 30 mg once daily, brepocitinib 15 mg once daily, or placebo for 52 weeks. Background standard therapies were continued and glucocorticoids were tapered. What did the trial show? Group Mean Total Improvement Score at Week 52 Brepocitinib 30 mg 46.5 Brepocitinib 15 mg 37.5 Placebo 31.2 The 30-mg dose was significantly superior to placebo for the primary endpoint. Importantly, brepocitinib 30 mg was also superior across all nine key secondary endpoints, including skin disease activity, systemic glucocorticoid tapering and functional disability. Improvements in some outcomes were observed as early as week 4. It was not just about muscle enzymes One of the clinically attractive aspects of the VALOR results is that benefit was not restricted to a laboratory value. Dermatomyositis can produce persistent and troublesome cutaneous disease even when muscle manifestations are less dramatic. The 30-mg dose demonstrated improvement across clinically relevant domains including skin activity and physical function. The steroid-sparing angle Long-term glucocorticoid exposure carries substantial toxicity, including diabetes, osteoporosis, infection risk, cataracts, hypertension and weight gain. In VALOR, improvement with brepocitinib 30 mg was accompanied by greater glucocorticoid tapering. This makes the result clinically more meaningful than a change in a single disease marker. Does this replace steroids? No. The approval should not be interpreted as meaning that every newly diagnosed patient can simply replace conventional therapy with one tablet. Dermatomyositis is heterogeneous. Treatment decisions still depend on the severity and pattern of muscle disease, dysphagia, respiratory involvement, interstitial lung disease, skin disease, autoantibody profile, malignancy evaluation, previous treatment response and patient-specific risks. Also remember an important trial detail: standard therapies were continued while glucocorticoids were tapered. Brepocitinib adds a new targeted option; it does not erase the need for individualized specialist management. Dose: the number worth remembering The FDA-approved Lisraya tablet contains brepocitinib 30 mg, administered orally once daily for adults with dermatomyositis. Safety: oral does not mean casual Brepocitinib is a potent immunomodulatory therapy. In VALOR, serious infections occurred more frequently with brepocitinib 30 mg than with placebo (10% versus 1%). The FDA prescribing information contains important warnings and precautions, including serious infections, malignancy, major adverse cardiovascular events and thrombosis. Common adverse reactions reported in the FDA medication information include upper respiratory tract infections, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, falls, influenza and acne. Clinical message: “Oral” should never be confused with “low-risk.” Appropriate patient selection, screening and monitoring remain essential. What should medical students remember? Drug: Brepocitinib Trade name: Lisraya Route: Oral, once daily Dose: 30 mg once daily Mechanism: Selective TYK2-JAK1 inhibitor Indication: Dermatomyositis in adults FDA approval: August 27, 2026 Key trial: VALOR Potential exam question A patient with dermatomyositis is started on a newly FDA-approved oral therapy that selectively inhibits TYK2 and JAK1. Which drug is most likely being prescribed? Answer: Brepocitinib (Lisraya). The bigger lesson: targeted therapy is entering myositis For years, dermatomyositis was taught through its memorable clinical signs: heliotrope rash, Gottron papules and proximal muscle weakness. Those remain fundamental. But modern medicine increasingly asks a second question: which molecular pathways are driving the disease, and can those pathways be targeted? Brepocitinib represents that transition from broad immunosuppression toward more targeted immune modulation. Its ultimate place in treatment algorithms will continue to evolve with real-world experience, longer-term safety data, accessibility and cost. But the 2026 approval itself is already an important milestone in dermatomyositis therapy. Frequently Asked Questions What is the new oral drug for dermatomyositis? Brepocitinib, marketed as Lisraya, was FDA-approved in August 2026 for the treatment of dermatomyositis in adults. What is the mechanism of brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1, modifying cytokine signaling involved in inflammatory and autoimmune pathways. What is the dose of brepocitinib for dermatomyositis? The FDA-approved Lisraya dose is 30 mg orally once daily. Is brepocitinib a JAK inhibitor? Yes. Brepocitinib selectively inhibits TYK2 and JAK1. Is brepocitinib better than steroids for dermatomyositis? The treatments should not be reduced to a simple either-or comparison. In VALOR, background standard therapies were continued while glucocorticoids were tapered. The 30-mg brepocitinib group showed clinical benefit and greater glucocorticoid tapering. What is the most important safety concern? Serious infection risk is important. The FDA label also contains warnings and precautions regarding malignancy, major adverse cardiovascular events and thrombosis. What should NEET-PG and INI-CET students remember? Brepocitinib → oral TYK2-JAK1 inhibitor → adult dermatomyositis. Remember the 30-mg once-daily dose […]

Medical

How I Cracked FMGE July 2025: My Strategy, High-Yield Topics & Motivation

Hi, future doctors! I’m one of you — a fellow foreign medical graduate who once sat exactly where you are today. With hope in my heart and fear in my gut, I prepared for the FMGE. And today, I’m writing this as someone who cracked the FMGE July 2025 exam — and walked out victorious. This post is everything I wish someone had handed me when I started my journey. 📅 FMGE July 2025: Study Timeline & Strategy “Success doesn’t come from what you do occasionally. It comes from what you do consistently.” 🧩 April 29 – May 15: Foundation Building Start with FMGE Solutions book — subject-wise Make concise, functional notes Use 1 primary video source + FMGE Solutions (avoid content overload) 🚀 May 16 – June 20: Deep Dives 3–4 days for short subjects, 5–6 days for long ones Solve MCQs immediately after theory from FMGE Solutions Weekend revision of all studied content 🔥 June 21 – July 10: Full Revision Phase Daily subject-wise revision + MCQ practice Mock tests under exam conditions 🌟 July 11 – July 20: Image-based & Final Recall Focus on visuals, PYQs, and sticky topics Highlight-rich revision using FMGE Solutions 💆‍♂️ July 21 – 25: Calm Before the Exam No new material — revise what you know Trust your notes, mock results, and FMGE Solutions 📘 FMGE Solutions Book: My Lifesaver The FMGE Solutions book was my single most powerful tool. Its explanations were lucid, recall-focused, and tailored for the FMGE format. Every answer had logic — not just memorization PYQs covered in depth — linked with concept Color-coded tables and images — a visual treat! Pro tip: If you’re ever lost, do FMGE Solutions + notes + mock tests. It’s more than enough. 🎯 Exhaustive List of High-Yield Topics for FMGE 2025 This list is my battle map — distilled from FMGE Solutions, recall sessions, and subject experts. 🧠 Medicine ECG patterns, TB regimens, ABG interpretation SLE criteria, Rheumatology markers, Iron studies 🪒 Surgery Hernia types, Burn fluid formula, Shock classification Thyroid FNAC, ATLS trauma steps 👶 Pediatrics Vaccines, milestones, congenital defects, PEM 👩‍⚕️ OBG FIGO staging, eclampsia, TORCH, labor stages 🧪 Pathology Cell injury, Lymphomas, Tumor markers, Clotting cascade 🧬 Microbiology Sterilization, Culture media, HIV, Zoonoses 💊 Pharmacology Schedules, Antidotes, Emergency drugs, Autonomic drugs 📊 PSM IMNCI, ORS, Biases, Health goals, Committees 🦷 Short Subjects Ophthalmology, ENT, Psychiatry, Forensic — focus on clinical signs, IPC sections, reflexes, and emergency care points. 💖 Motivation Pumps (For When You Feel Like Quitting) You are not here by accident. You didn’t survive a whole medical degree abroad to give up now. You are meant to cross this line — and I promise you will. There were nights I cried silently. But when I opened FMGE Solutions again, I felt like someone had my back. Keep going — there’s light ahead, and it’s got your name on it. 📝 Practice Strategy & Mistakes to Avoid ✅ Daily To-Do Mixed MCQs (3 hours daily) 1 Short subject + 1 High-yield topic revision Recall sessions on YouTube ❌ Avoid These Mistakes Switching books last minute Over-studying rare topics Burnout from 12+ hour days without breaks Not revising your wrong MCQs! 🎓 Final Words Before July 26, 2025 Close your books the night before. Trust the work you’ve done. Let your parents hug you and tell you how proud they are. Sleep. Smile. Go write your history. And when the clock starts ticking on exam day, say to yourself: “I am calm. I am ready. I deserve this.”

Medical

White Coat Hypertension vs Masked Hypertension

One causes over diagnosis and other one causes under diagnosis of hypertension. Learn the nuances of difference between both of them in next 1 minute of careful reading. Reading improves skill set. Watching reels decreases concentration span and students are not able to answer in real exam scenarios. Feature White Coat Hypertension Masked Hypertension Clinic BP High Normal Home/Ambulatory BP Normal High Cause Anxiety or stress during medical visits Blood pressure elevated during daily life but normal in clinic Risk of missed diagnosis May lead to overdiagnosis May lead to underdiagnosis Cardiovascular risk Lower than sustained hypertension but higher than normotension Similar to sustained hypertension; significant CV risk Example Clinic 150/95 mmHg Home 120/75 mmHg Clinic 125/80 mmHg Home 145/90 mmHg Diagnosis HBPM or 24-hour ABPM HBPM or 24-hour ABPM Management Lifestyle measures and follow-up; medication only if persistent hypertension develops or high risk Treat as true hypertension with lifestyle modification and antihypertensive therapy when indicated Easy Memory Hack White Coat: High blood pressure only when the doctor is watching. Masked: Hypertension is hidden in the clinic but present in everyday life

Medical

First Targeted Drug for Hepatitis D Every NEET PG Aspirant Must Know

Why is Hepatitis D Important? Hepatitis D virus (HDV) leads to faster progression of chronic viral hepatitis and can even lead to Fulminant hepatic failure.  It cannot survive on its own because it is a defective RNA virus that requires the HBsAg (Hepatitis B surface antigen) of Hepatitis B virus to enter hepatocytes and replicate. Golden Rule: No Hepatitis B = No Hepatitis D Patients with HDV progress much faster to: Cirrhosis Liver failure Hepatocellular carcinoma (HCC) Introducing Hepcludex (Bulevirtide) Bulevirtide (Brand: Hepcludex) is the first approved drug specifically designed for chronic Hepatitis D infection.   Mechanism of Action HDV enters hepatocytes by binding to the NTCP receptor (Sodium Taurocholate Cotransporting Polypeptide) present on liver cells. Bulevirtide blocks the NTCP receptor, thereby preventing: Entry of HDV Entry of HBV Infection of new hepatocytes   Easy Mnemonic Bulevirtide = BLOCKS the Liver Entry of Hepatitis B and Hepatitis D viruss   Indications Approved for: Chronic Hepatitis D Patients with compensated liver disease Usually given along with suppression of HBV replication using nucleos(t)ide analogues when indicated. Route Subcutaneous injection Once daily   Major Side Effects Common adverse effects include: Injection site reactions Elevated bile acids (expected because NTCP transports bile acids) Headache Fatigue Nausea   Why is This Drug Unique? Unlike conventional antivirals that inhibit viral replication, Bulevirtide prevents viral entry into liver cells. It is therefore called an entry inhibitor.   Previous Standard Therapy Earlier treatment relied mainly on: Pegylated Interferon-α Limitations: Low response rates Significant adverse effects Poor tolerability Bulevirtide has provided a major advance in the management of chronic HDV.   NEET PG MCQ A patient with chronic Hepatitis D is started on Hepcludex. Which of the following best describes its mechanism of action? Inhibits HBV DNA polymerase Inhibits viral RNA polymerase Blocks NTCP receptor-mediated viral entry into hepatocytes Inhibits viral protease Answer: C Explanation: Bulevirtide is the first HDV entry inhibitor. It blocks the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes, preventing HBV and HDV entry into liver cells.   Take-Home Message If you remember just one line for your exam: Hepcludex (Bulevirtide) = NTCP blocker = Entry inhibitor = First targeted drug for chronic Hepatitis D

Medical

2026 AHA/ACC Pulmonary Embolism (PE) Classification

sPESI – Pulmonary embolism severity index Mnemonic: COPS BP 100 /80A Cancer, Chronic cardiopulmonary disease, oxygen saturation, pulse rate > 100/min, SBP < 100 mm Hg and Age > 80 years Class Meaning Clinical Features Preferred Initial Anticoagulation Reperfusion Strategy Memory Hack A Asymptomatic PE Incidental PE, no symptoms DOAC or LMWH (Enoxaparin) Not usually required A = Accidental finding B Low-risk symptomatic PE S-PESI = 0   stable DOAC or LMWH (Enoxaparin) None B = breathing comfortably/ Backpack home C Compensated PE Elevated s-PESI but no impending shock LMWH (Enoxaparin); UFH if procedure likely Usually anticoagulation alone C = Careful monitoring D Decompensating PE Normotensive with evidence of impending circulatory collapse (e.g., elevated lactate, AKI, oliguria, altered mental status, low cardiac output) IV Unfractionated Heparin (UFH) PERT evaluation; consider catheter-directed therapy, systemic thrombolysis, or embolectomy D = Deteriorating despite normal blood pressure E Extreme PE Persistent hypotension, obstructive shock, vasopressors, or cardiac arrest IV Unfractionated Heparin (UFH) Immediate systemic thrombolysis if eligible, or catheter thrombectomy/surgical embolectomy E = Emergency   Category C Subclassification Subtype RV Dysfunction Troponin Memory Hack C1 Absent Absent 1 = None positive C2 Present or Absent Absent or Present 2 = One positive C3 Present Present 3 = Two positives High-Yield Anticoagulation Stable (Classes A–C): DOAC or LMWH (Enoxaparin); UFH may be preferred in selected Class C patients if an invasive procedure is anticipated. Unstable (Classes D–E): IV Unfractionated Heparin (UFH) is preferred because it is rapidly reversible and is ideal when thrombolysis, catheter-based intervention, or surgery may be be required.

Medicine

Once-Weekly Insulin Approved in India: A New Era in Diabetes Management

For the first time, once-weekly basal insulin has been approved in India, marking one of the biggest advances in insulin therapy in decades. The approved molecule is Insulin Icodec, a long-acting basal insulin designed to provide 7-day glucose control with a single weekly injection. What is Insulin Icodec? Insulin Icodec is an ultra-long-acting basal insulin analogue developed for adults with diabetes requiring basal insulin therapy. Key Point 1 injection every week Replaces 7 daily basal insulin injections   How Does It Last for 7 Days? Insulin Icodec has been engineered to: Bind strongly to albumin Be released slowly into circulation Maintain stable insulin levels throughout the week This provides a continuous basal insulin effect without major peaks.   Advantages Over Daily Basal Insulin   Only 1 injection per week Better treatment adherence Reduced injection fatigue Similar HbA1c reduction compared with daily basal insulin in clinical trials May improve patient satisfaction and quality of life   Which Patients May Benefit? Once-weekly insulin may be considered for: Type 2 diabetes requiring basal insulin Patients reluctant to start insulin because of daily injections Individuals with poor adherence to daily basal insulin Clinical use should always follow physician guidance and approved prescribing recommendations. Is It for Type 1 Diabetes? Current approval and clinical use primarily focus on adults with Type 2 diabetes requiring basal insulin. Its role in Type 1 diabetes remains more limited and depends on regulatory approvals and clinical guidance. Important Clinical Points It is basal insulin, not mealtime insulin. Rapid-acting insulin is still required when indicated. Weekly dosing requires careful initiation and dose titration. Missing one dose can have a larger impact than missing a single daily basal dose. NEET PG Pearls Feature High-Yield Fact Drug Insulin Icodec Frequency Once weekly Type Ultra-long-acting basal insulin Major Benefit Improves adherence by reducing injections Replaces Daily basal insulin Not Used As Prandial (mealtime) insulin   Memory Trick ICODEC = I COME Once Every Week Remember: Icodec is Once Weekly Basal Insulin   NEET PG/ INICET / FMGE MCQ A newly approved basal insulin in India provides glycemic control with a single injection every week. Which insulin is being described? Insulin Lispro Insulin Glargine Insulin Icodec Insulin Aspart Answer: C. Insulin Icodec Explanation: Insulin Icodec is an ultra-long-acting basal insulin analogue that maintains glucose control for one week, significantly reducing the number of injections required compared with conventional daily basal insulin. Dr Marwah NEET PG Educator for 2 decades generating good, ethical doctors   Links of must watch videos of this channel https://www.youtube.com/watch?v=5reXtUFW-Y0 https://www.youtube.com/watch?v=K-YNyzLENEE https://www.youtube.com/live/houmdnMAmdI

Medical

How I Cracked FMGE July 2025: My Strategy, High-Yield Topics & Motivation

Hi, future doctors! I’m one of you — a fellow foreign medical graduate who once sat exactly where you are today. With hope in my heart and fear in my gut, I prepared for the FMGE. And today, I’m writing this as someone who cracked the FMGE July 2025 exam — and walked out victorious. This post is everything I wish someone had handed me when I started my journey. 📅 FMGE July 2025: Study Timeline & Strategy “Success doesn’t come from what you do occasionally. It comes from what you do consistently.” 🧩 April 29 – May 15: Foundation Building Start with FMGE Solutions book — subject-wise Make concise, functional notes Use 1 primary video source + FMGE Solutions (avoid content overload) 🚀 May 16 – June 20: Deep Dives 3–4 days for short subjects, 5–6 days for long ones Solve MCQs immediately after theory from FMGE Solutions Weekend revision of all studied content 🔥 June 21 – July 10: Full Revision Phase Daily subject-wise revision + MCQ practice Mock tests under exam conditions 🌟 July 11 – July 20: Image-based & Final Recall Focus on visuals, PYQs, and sticky topics Highlight-rich revision using FMGE Solutions 💆‍♂️ July 21 – 25: Calm Before the Exam No new material — revise what you know Trust your notes, mock results, and FMGE Solutions 📘 FMGE Solutions Book: My Lifesaver The FMGE Solutions book was my single most powerful tool. Its explanations were lucid, recall-focused, and tailored for the FMGE format. Every answer had logic — not just memorization PYQs covered in depth — linked with concept Color-coded tables and images — a visual treat! Pro tip: If you’re ever lost, do FMGE Solutions + notes + mock tests. It’s more than enough. 🎯 Exhaustive List of High-Yield Topics for FMGE 2025 This list is my battle map — distilled from FMGE Solutions, recall sessions, and subject experts. 🧠 Medicine ECG patterns, TB regimens, ABG interpretation SLE criteria, Rheumatology markers, Iron studies 🪒 Surgery Hernia types, Burn fluid formula, Shock classification Thyroid FNAC, ATLS trauma steps 👶 Pediatrics Vaccines, milestones, congenital defects, PEM 👩‍⚕️ OBG FIGO staging, eclampsia, TORCH, labor stages 🧪 Pathology Cell injury, Lymphomas, Tumor markers, Clotting cascade 🧬 Microbiology Sterilization, Culture media, HIV, Zoonoses 💊 Pharmacology Schedules, Antidotes, Emergency drugs, Autonomic drugs 📊 PSM IMNCI, ORS, Biases, Health goals, Committees 🦷 Short Subjects Ophthalmology, ENT, Psychiatry, Forensic — focus on clinical signs, IPC sections, reflexes, and emergency care points. 💖 Motivation Pumps (For When You Feel Like Quitting) You are not here by accident. You didn’t survive a whole medical degree abroad to give up now. You are meant to cross this line — and I promise you will. There were nights I cried silently. But when I opened FMGE Solutions again, I felt like someone had my back. Keep going — there’s light ahead, and it’s got your name on it. 📝 Practice Strategy & Mistakes to Avoid ✅ Daily To-Do Mixed MCQs (3 hours daily) 1 Short subject + 1 High-yield topic revision Recall sessions on YouTube ❌ Avoid These Mistakes Switching books last minute Over-studying rare topics Burnout from 12+ hour days without breaks Not revising your wrong MCQs! 🎓 Final Words Before July 26, 2025 Close your books the night before. Trust the work you’ve done. Let your parents hug you and tell you how proud they are. Sleep. Smile. Go write your history. And when the clock starts ticking on exam day, say to yourself: “I am calm. I am ready. I deserve this.”

FMGE, INICET, Medical

STROKE

DIAGNOSIS For any neurological emergency first secure airway, check BP and calculate NIHSS. National institute of health stroke scale value > 5 confirms stroke Best initial step: Head CT without contrast to differentiate ischemic from hemorrhagic stroke and identify potential candidates for thrombolytic therapy. If CT head is normal and no evidence of CNS bleed in present in symptomatic patient it implies Acute ischemia stroke Labs to draw immediately, in case thrombolytic therapy or intervention may be required, include CBC, Random blood sugar, coagulogram, cardiac biomarkers and KFT CTA is done after fibrinolysis to determine opening of large vessel occlusion Investigations NCCT head ECG Echo Holter Carotid doppler Transcranial doppler Conventional Angiography Common Stroke Symptoms by Vessel Territory  VESSEL TERRITORY  Characteristic features   Middle cerebral artery Patient looks towards the side of lesion Contralateral paresis and sensory loss in the face and arm Homonymous hemianopsia Global Aphasia for dominant lobe lesion Neglect and constructional apraxia for non-dominant lobe lesion   Anterior cerebral artery Contralateral paresis and sensory loss in the leg Aggressive behavior with personality changes Abulia Urinary incontinence Posterior cerebral artery P1 PCA: Weber syndrome I/L 3rd nerve palsy with contralateral hemiparesis   P1 PCA: Nothnagel syndrome I/L 3rd nerve palsy with contralateral limb ataxia Lacunar Pure motor paralysis due to damage to posterior limb of internal capsule Pure sensory stroke Ataxic hemiparesis, dysarthria, or clumsy hand Strokes affecting the thalamus may cause thalamic pain syndrome several weeks after the event, patient complaints of burning pain over hand, arm, leg on even touch   Transient ischemic attack Any 1 of the symptoms above depending on location of vascular lesion and 1.       Neurologic deficit lasts < 24 hours (most last < 1 hour) 2.       DW MRI will be normal   Wallenberg syndrome due to vertebral artery involvement Loss of pain and temperature sensation on ipsilateral face and contralateral body Ipsilateral bulbar weakness Ipsilateral Horner syndrome Vertigo Nystagmus Carotid artery dissection Sudden headache, neck pain, Horner syndrome Treatment of acute ischemic stroke < 6 hours 6 -24 hours Fibrinolysis but BP should be less than < 185/110 mm Hg If BP remains more than the cut off mentioned then Schedule thrombectomy Thrombectomy after conventional cerebral angiography Ideal window period for acute ischemic stroke is 4.5 hours but can be done up to 6 hours Treat fever and hyperglycemia as both are associated with poorer prog- noses in the setting of acute stroke. Monitor for signs and symptoms of brain swelling, raised intracranial pressure and herniation. Treat acutely with mannitol and Prevent and treat poststroke complications, such as aspiration pneumonia, urinary tract infection (UTI), and deep vein thrombosis (DVT). Contraindications to fibrinolysis Stroke or head trauma within the last 3 months Anticoagulation with INR > 1.7 MI in past 3 months Prior intracranial hemorrhage Elevated BP: Systolic > 185 mm Hg or diastolic 110 mm Hg Major Surgery in the past 14 days On discharge the following measures are to be introduced – Hypertension treatment with target BP of < 130/80 mm Hg Keep HbA1c < 7% Statins Acetylsalicylic acid and ticagrelor (dual antiplatelet therapy) For cardioembolic strokes due to atrial fibrillation, target INR is 2-3. In Cases in India involving a prosthetic valve deployed for calcified mitral valve, the target INR is 2.5-3.5. Carotid endarterectomy: If stenosis is > 60% in symptomatic patients or >70% in asymptomatic patients (contraindicated in complete occlusion)

FMGE, INICET, NEET PG, NExT

Anaphylactic Shock and Its Management: A Comprehensive Guide

Anaphylactic shock is the most severe form of allergic reaction and it is characterized by a combination of the following life-threatening symptoms in patient after parenteral drug administration or vaccine. It can occur within seconds to minutes making it a difficult case to handle. Severe Hypotension: As the blood vessels dilate and fluids leak into surrounding tissues, the volume of blood circulating through the body decreases, leading to shock. This can result in the organs not receiving enough oxygen and nutrients, causing them to malfunction. Airway Obstruction: Laryngeal oedema, swelling of the throat or tongue can block the airway, making it difficult to breathe and presents as stridor. This is a critical concern and can lead to respiratory failure without prompt treatment. This is coupled with bronchospasm and wheeze. Loss of Consciousness: Due to low blood pressure and inadequate oxygen supply to the brain, individuals may faint or become unresponsive. Multiple Organ Involvement: Anaphylactic shock can affect vital organs, including the heart, lungs, liver, and kidneys. Without rapid intervention, the situation can quickly become fatal. Common Triggers of Anaphylactic Shock Understanding the common triggers for anaphylaxis is crucial for prevention and management. The most frequent triggers include: Food Allergies: Certain foods, especially peanuts, tree nuts, shellfish, eggs, and milk, are among the most common culprits. These foods can provoke an immune response in individuals with allergies to them. Insect Stings: Bee stings, wasp stings, or bites from other insects like hornets can cause anaphylaxis in people allergic to venom. Medications: Antibiotics (like penicillin) and non-steroidal anti-inflammatory drugs (NSAIDs) can trigger severe allergic reactions in some individuals. Latex: Latex allergies are common, particularly in healthcare settings where gloves and other medical devices made from latex are frequently used. Other Allergens: Although less common, some people may experience anaphylaxis due to allergens like pollen, mold, or animal dander. Symptoms of Anaphylactic Shock The symptoms of anaphylaxis typically occur rapidly after exposure to an allergen. They can range from mild to severe and affect multiple body systems. Common symptoms include: Skin reactions: Hives, itching, redness, or swelling (especially around the eyes, lips, and throat). Respiratory symptoms: Difficulty breathing, wheezing, throat tightness, swelling of the tongue or throat, and hoarseness. Cardiovascular symptoms: Dizziness, fainting, rapid heartbeat (tachycardia), or a drop in blood pressure (hypotension), which may cause shock. Gastrointestinal symptoms: Nausea, vomiting, abdominal cramps, or diarrhea. Neurological symptoms: Anxiety, confusion, and loss of consciousness in severe cases. Management of Anaphylactic Shock Immediate treatment is essential for anaphylactic shock. The following are the primary management strategies to mitigate the effects of anaphylaxis and prevent death: 1. Administer Epinephrine (Adrenaline) The first and most critical step in managing anaphylaxis is to administer epinephrine (adrenaline). Epinephrine is a life-saving medication that works quickly to counteract the severe allergic response. It constricts blood vessels, raises blood pressure, reduces swelling, and helps relax the muscles in the airways, improving breathing. Epinephrine is usually administered through an intramuscular injection, commonly in the thigh. For people at risk of anaphylaxis, carrying an epinephrine auto-injector (e.g., EpiPen) is essential. If you suspect anaphylaxis, inject the epinephrine as soon as possible and seek emergency medical help. 2. Call Emergency Medical Services (EMS) Anaphylaxis can recur, and additional medical intervention may be necessary. Medical personnel can administer further doses of epinephrine, antihistamines, corticosteroids, or other medications to stabilize the individual. 3. Lay the Person Down and Elevate Their Legs If the person is conscious, help them lie down with their legs elevated. This position helps to increase blood flow to vital organs and can prevent fainting or shock. However, if the person is having difficulty breathing, allow them to sit up or find a position that is more comfortable. 4. Administer Antihistamines and Corticosteroids Antihistamines (such as diphenhydramine) can help reduce some of the symptoms of anaphylaxis, such as hives and itching, but they should not replace epinephrine. Corticosteroids may be used to reduce inflammation and prevent the recurrence of symptoms, but they take longer to work and should not be the first line of defense. 5. Oxygen Therapy In severe cases, oxygen may be required to help the person breathe and maintain adequate oxygen levels in the blood. This is typically administered in a medical setting. 6. Observation and Follow-Up Care Even after initial treatment with epinephrine, the person should be observed for at least 4-6 hours in a medical facility. Anaphylaxis can recur, and additional doses of epinephrine may be required. Prevention of Anaphylactic Shock While anaphylactic shock is an emergency, prevention is the best strategy. Here are some tips to minimize the risk of anaphylaxis: Identify and Avoid Triggers: If you know what causes your allergic reactions, avoid those allergens. For example, if you’re allergic to peanuts, make sure to avoid foods that contain peanuts or are processed in facilities that handle peanuts. Carry Epinephrine: Anyone at risk for anaphylaxis should always carry an epinephrine auto-injector. Ensure that it is easily accessible and not expired. Wear Medical Identification: A medical alert bracelet or necklace can inform others about your allergies in case of an emergency. Educate Others: Make sure your family, friends, coworkers, and others know how to recognize the signs of anaphylaxis and how to use an epinephrine auto-injector if necessary. Work with a Healthcare Provider: If you have a history of severe allergic reactions, work with your doctor to develop a personalized action plan. This plan will help you avoid triggers and know what steps to take in the event of an anaphylactic reaction.

Scroll to Top